Form 4: RxSight Executive Ilya Goldshleger Executes Stock Option and Sells Shares

RxSight's Co-President and COO, Ilya Goldshleger, exercised stock options and sold shares under a pre-arranged trading plan.

Summary

• Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc., exercised stock options to acquire 1,330 shares of common stock at a price of $15.08 per share.
• Concurrently, Mr. Goldshleger sold 1,330 shares of common stock at a weighted average price of $46.1325 per share, with individual sales ranging from $46.00 to $46.32.
• These transactions were executed on November 12, 2024, under a Rule 10b5-1 trading plan adopted on June 3, 2024.
• Following these transactions, Mr. Goldshleger directly owns 42,246 shares of common stock and indirectly owns 1,372 shares through his spouse.
• He also holds options for 58,057 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither particularly positive nor negative.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although these were pre-planned.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2024.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies like RxSight, similar to practices at companies such as Alcon (ALC) and Johnson & Johnson (JNJ) where executives often have pre-arranged trading plans.
• The vesting schedule of the options, with 1/48th vesting monthly, is a typical vesting schedule for stock options in the technology and medical device industries, similar to vesting schedules at companies like Intuitive Surgical (ISRG) and Medtronic (MDT).

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.

Key Dates

Keywords

stock options, insider trading, Rule 10b5-1, executive compensation, share sale, RxSight, RXST